Trials / Recruiting
RecruitingNCT04981145
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome: a Multi-center, Prospective, Open Study
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iguratimod Tablets | Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks. |
| DRUG | Hydroxychloroquine Sulfate Tablets | Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks. |
Timeline
- Start date
- 2022-01-14
- Primary completion
- 2024-12-01
- Completion
- 2025-07-01
- First posted
- 2021-07-28
- Last updated
- 2024-10-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04981145. Inclusion in this directory is not an endorsement.